Baird lowered its price target on Gilead Sciences (NASDAQ: GILD) to $79.00 (from $87.00) while maintaining an Outperform rating on ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Gilead Sciences (GILD) PT Lowered to $90 at RBC CapitalMay 2, 2018 8:26 AM Gilead Sciences (GILD) PT Lowered to $81 at Morgan StanleyMay 2, 2018 7:45 AM Gilead Sciences (GILD) PT Lowered to $89 at Maxim GroupMay 2, 2018 7:42 AM Too many cancer drugs? Crowded market gives investors pauseMay 2, 2018 7:14 AM Gilead Sciences (GILD) PT Lowered to $85 at CowenMay 2, 2018 6:31 AM Gilead Sciences (GILD) PT Lowered to $72 at Leerink PartnersMay 2, 2018 6:23 AM Gilead (GILD) volatility elevated into less than expected Q1 results May 2, 2018 3:54 AM Gilead Sciences (GILD) PT Lowered to $90 at BarclaysMay 2, 2018 3:54 AM Gilead Sciences (GILD) Misses Q1 EPS by 19c, Reiterates FY GuidanceMay 1, 2018 4:02 PM Gilead Sciences Announces Second Quarter 2018 DividendMay 1, 2018 4:02 PM